<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060684</url>
  </required_header>
  <id_info>
    <org_study_id>AZA I-06</org_study_id>
    <nct_id>NCT00060684</nct_id>
    <nct_alias>NCT00057772</nct_alias>
  </id_info>
  <brief_title>Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to determine the appropriate dose of pixantrone to be used in this
      combination and obtain data on the combination's safety and activity profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FND-R regimen is commonly used in the treatment of indolent Non-Hodgkin's lymphoma (NHL)
      and contains the chemotherapy agents mitoxantrone, fludarabine, dexamethasone (a steroid) and
      the monoclonal antibody rituximab. In this trial we are replacing mitoxantrone with
      pixantrone, an agent with a similar chemical structure (both agents are DNA intercalators).
      The trial is being run in patients with relapsed or refractory indolent NHL and aims to
      define the appropriate dose of pixantrone to be used in this combination, as well as to
      obtain data on pixantrone's safety and activity profile in combination with these drugs.

      This trial is expected to recruit up to 30 patients in the USA. Patients will be treated with
      the drug combination for up to eight months and then followed closely in the four-week period
      after the last administration. After that, patients will receive physician check-ups every
      three months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine MTD</measure>
    <time_frame>Per cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish safety profile</measure>
    <time_frame>per cycle</time_frame>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Lymphoma, Low-Grade</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <condition>Lymphoma, Mixed-Cell, Follicular</condition>
  <condition>Lymphoma, Small Cleaved-Cell, Follicular</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pixantrone (BBR 2778)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients with relapsed or refractory indolent (low-grade) NHL

          -  Who have received 1-3 prior treatments with chemotherapy

        Exclusion criteria

          -  Patients previously treated with fludarabine

          -  Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or
             partial response (PR) to that treatment

          -  Patients known to have an allergic reaction to rituximab, or to murine proteins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Stromatt, MD</last_name>
    <role>Study Director</role>
    <affiliation>CTI BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Onc/Hem Consultants, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer. 2011 Nov 15;117(22):5067-73. doi: 10.1002/cncr.26121. Epub 2011 Jun 16.</citation>
    <PMID>21681734</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2003</study_first_submitted>
  <study_first_submitted_qc>May 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2003</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <name_title>Gabriella Camboni, M.D.</name_title>
    <organization>Cell Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Pixantrone</keyword>
  <keyword>BBR 2778</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>DNA Intercalator</keyword>
  <keyword>mitoxantrone</keyword>
  <keyword>fludarabine</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Mabthera</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>antibody</keyword>
  <keyword>NHL</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>indolent</keyword>
  <keyword>low grade</keyword>
  <keyword>Novuspharma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Pixantrone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

